Earnings Release • Oct 9, 2015
Earnings Release
Open in ViewerOpens in native device viewer
Fagron's consolidated turnover increased by 2.4% (3.5% at constant exchange rates) to $\epsilon$ 113.5 million during the third quarter of 2015. In organic terms, the turnover decreased by 3.8% (-2.7% at constant exchange rates).
| Turnover ( $x \in 1,000$ ) | O 3 2015 | Q3 2014 | Total growth |
Total growth CER |
Org. growth |
Org. growth CER |
|---|---|---|---|---|---|---|
| Fagron | 111.720 | 109,055 | 2.4% | 3.8% | $-3.8\%$ | $-2.5%$ |
| HL Technology | 1.818 | 1.845 | $-1.5%$ | $-12.1%$ | $-1.5%$ | $-12.1%$ |
| Total | 113,538 | 110,900 | 2.4% | 3.5% | $-3.8%$ | $-2.7%$ |
| Turnover ( $x \in 1,000$ ) | 9M 2015 | $\sqrt{9M}$ 2014 | Total growth |
`otal growth CER |
Org. growth |
Org. growth CER. |
|---|---|---|---|---|---|---|
| Fagron | 349,988 | 313,185 | 11.8% | 8.3% | 4.2% | 1.0% |
| HL Technology | 7.317 | 6.863 | 6.6% | $-7.0\%$ | 6.6% | $-7.0\%$ |
| Total | 357,305 | 320.048 | 11.6% | 8.0% | 4.2% | 0.8% |
CER = constant exchange rates
Ger van Jeveren, CEO of Fagron: "This was a challenging quarter for Fagron. In Europe, our biggest market, good organic growth was achieved in all segments in which we are active. We also saw strong organic growth in Brazil, but the further weakening of the Brazilian real had a negative impact on the turnover in euros. We also experienced a setback in the United States because of the change in the reimbursement system for non-sterile preparations, which came into effect in May of this year. The effect of this change on the turnover of the third quarter was approximately € 17 million. The sterile FSPS activities in the United States have shown strong organic growth, mainly driven by growing demand from hospitals to outsource sterile preparations.
The change in the reimbursement system and continuing effects of this and the weakening of the Brazilian real have resulted in an adjustment of the outlook for 2015. As already announced last week, we expect to achieve turnover of between $\epsilon$ 470 and $\epsilon$ 480 million2 in 2015 with REBITDA3 of between $\epsilon$ 105 and $\epsilon$ 115 million4. The consequences of the revised REBITDA expectation for the full year of 2015 for the financing of Fagron are being addressed."
<sup>1 This press release was sent out by Fagron NV and Fagron BV.
<sup>2 Based on constant exchange rates (euro/US dollar 1.114 and euro/Brazilian real 3.524).
<sup>3.EBITDA before non-recurrent result.
<sup>4 Based on constant exchange rates (euro/US dollar 1.114 and euro/Brazilian real 3.524).
| Turnover ( $x \in 1,000$ ) | Q3 2015 | Q3 2014 | Total growth |
Total growth CER |
Org. growth |
Org. growth CER. |
|---|---|---|---|---|---|---|
| Fagron Specialty Pharma Services | 45,905 | 37.856 | 21.3% | 12.7% | 5.4% | $-2.1%$ |
| Fagron Trademarks | 12.424 | 11.229 | 10.7% | 23.2% | 10.7% | 23.2% |
| Fagron Essentials | 53.391 | 59.970 | $-11.0%$ | $-5.4%$ | $-13.0%$ | $-7.6%$ |
| Total | 111.720 | 109.055 | 2.4% | 3.8% | $-3.8%$ | $-2.5%$ |
| Turnover ( $x \in 1,000$ ) | $9M$ 2015 | 9M 2014 | Total growth |
Total growth CER |
Org. growth |
Org. growth CER |
|---|---|---|---|---|---|---|
| Fagron Specialty Pharma Services | 138,072 | 95.210 | 45.0% | 33.5% | 17.9% | 8.5% |
| Fagron Trademarks | 37,976 | 33.907 | 12.0% | 15.1% | 12.0% | 15.1% |
| Fagron Essentials | 173,940 | 184.068 | $-5.5%$ | $-6.0\%$ | $-5.9%$ | $-6.4%$ |
| Total | 349.988 | 313,185 | 11.8% | 8.3% | 4.2% | 1.0% |
CER = constant exchange rates
The turnover of Fagron, at constant exchange rates, has shown a positive development in the third quarter in all continents in which Fagron is active, except for the United States. Several initiatives are launched to counter the negative consequences of the change in the reimbursement system for non-sterile preparations in the United States. New concepts and trademarks are launched, mainly focused on the cash market, in the nonsterile segment. In the sterile segment, Fagron is investing in the expansion of an integrated national Sales team to fully use the capacity of the new sterile GMP compounding facility in Wichita that will open in the fourth quarter. Fagron also initiated a cost-saving program for the whole Group, with the objective to structurally decrease the costs by € 10 million on an annual basis.
The table below gives an overview of the turnover development and currency effects in the third quarter (in comparison with the third quarter of 2014).
| $(x \in 1,000)$ | Impact |
|---|---|
| Turnover Q3 2014 | € 109,055 |
| Development Europe | $+£ 6,173$ |
| Development South America | $+£ 5,034$ |
| Development Rest of World | $+6.465$ |
| Development United States-Essentials and FSPS non-sterile | -€ 17,042 |
| Development United States - FSPS sterile | +€ 2,420 |
| Currency effect BRL/euro | $-6,145$ |
| Currency effect US\$/euro | +€ 4,746 |
| Currency effects other | $-6.95$ |
| Contribution acquisitions | +€ 7,109 |
| Turnover Q3 2015 | € 111,720 |
The turnover of Fagron Specialty Pharma Services ('FSPS') increased by 21.3% (12.7% at constant exchange rates) from € 37.9 million in the third quarter of 2014 to € 45.9 million in the third quarter of 2015. Organic turnover growth amounted to 5.4% (-2.1% at constant exchange rates).
Major investments are being made in the sterile segment to meet the growing demand from hospitals to outsource sterile preparations to Fagron Specialty Pharma Services. The antibiotics compounding facility in Hoogeveen (the Netherlands) will be operational in October 2015. The new 5,000 m2 sterile GMP and FDA 503B-registered compounding facility in Wichita (Kansas, United States) will become operational in November 2015. The construction of a new sterile GMP compounding facility in Johannesburg (South Africa) is on the agenda for 2016; the facility is expected to become operational in August 2016.
The turnover at Fagron Trademarks increased by 10.7% (23.2% at constant exchange rates) to $\epsilon$ 12.4 million during the third quarter of 2015.
Trademarks per Continent (Q3-15: € 12.4 million)
Innovation is the driving force behind the growth of Fagron Trademarks. Fagron's R&D team of 45 researchers and more than 300 pharmacists work closely with pharmacists, physicians and universities worldwide to develop new and innovative vehicles, concepts and formulations to fulfil the growing need for customized patient care.
In addition to the Fagron Trademarks already enjoying global success, such as SyrSpend® SF, Pentravan® and Fagron Advanced Derma, Fagron has a well-filled and growing pipeline of innovations which will be brought to market in the coming years.
The turnover at Fagron Essentials decreased by 11.0% (-5.4% at constant exchange rates) to $\epsilon$ 53.4 million during the third quarter of 2015. Organically the turnover decreased by 13.0% (-7.6% at constant exchange rates).
The project to optimize the product portfolio and production process that was started in the second quarter also impacted turnover in the third quarter. € 2 million of turnover in non-strategic, low margin products was phased out.
Fagron further consolidated its market leadership in the sale of pharmaceutical raw materials in the third quarter of 2015 with the acquisition of Belgian ABC Chemicals. ABC Chemicals is expected to generate turnover of € 5 million on an annual basis in 2015 and has an EBITDA margin comparable to that of the Fagron Group. This acquisition was concluded in July and will be consolidated from 1 July 2015.
HL Technology, the division focused on developing and introducing innovative precision components for the dental and orthopaedic industry, achieved turnover of €1.8 million during the third quarter of 2015, a decrease of 1.5% (-12.1% at constant exchange rates) compared to the third quarter of 2014.
Further to our press release of last week, we can confirm that Fagron has received a number of indications of interest in the form of non-binding offers in respect of the potential acquisition of Fagron.
After due consideration, taking into account the interests of all Fagron shareholders, as well as the interest of other stakeholders, the Board of Directors has decided to explore the possibility of a sale of the company. In this respect the Board of Directors has allowed a selected number of potential buyers to perform confirmatory due diligence on the company, with a view to preparing a binding offer, subject to customary conditions, for the company.
The Board has taken into consideration a number of factors, including, but not limited to price, reputation of the bidder, experience of the bidder in the sector or ancillary sectors, its knowledge of Fagron, its ability to add value to Fagron, its ability to finance a transaction and its ability and commitment to perform due diligence in a timely manner with minimum disruption to Fagron. All parties in the process are respected, credible and reputable international organisations.
The Board of Directors will carefully evaluate any binding offers, if and when made, consistent with its fiduciary duties taking into full consideration the interests of all its shareholders and other relevant stakeholders.
Further announcements will be made if and when circumstances so require.
Based on the current portfolio, Fagron expects to achieve turnover of between $\epsilon$ 470 and $\epsilon$ 480 million5 in 2015 with REBITDA6 of between € 105 and € 115 million7. The consequences of the revised REBITDA expectation for the full year of 2015 for the financing of Fagron are being addressed.
Ger van Jeveren (CEO) and Jan Peeters (CFO) will provide further details on the trading update for the third quarter of 2015 during a conference call scheduled for today. The conference call begins at 9:30 CET. From 5 to 10 minutes in advance you will be able to call in using the numbers and confirmation code below:
The Netherlands: +31 (0)20 721 9158 Belgium/Europe: +32 (0) 2 404 0662 North America: +1 212 444 0481 Confirmation code: 9494638
The presentation is as from publication of this press release available on http://investors.fagron.com/.
From 10:30 CET, the conference call can be heard on: The Netherlands: +31 (0)20 708 5013 Belgium/Europe: +32 (0)2 789 7487 North America: +1347 366 9565 Code to listen to the call: 9494638
From 10 October the conference call may be listened to or downloaded from Fagron's corporate website (http://investors.fagron.com/).
Publication of results for the 2015 financial year 5 February
Results and trading updates are published at 7:00 CET.
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.
Fagron is a scientific pharmaceutical R&D business focused on optimising and innovating personalised pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.
Constantijn van Rietschoten Chief Marketing Officer / Investor Relations ad interim Tel. +31(0)6 53 69 15 85 [email protected] investors.fagron.com
5 Based on constant exchange rates (euro/US dollar 1.114 and euro/Brazilian real 3.524).
<sup>6.EBITDA before non-recurrent result.
7 Based on constant exchange rates (euro/US dollar 1.114 and euro/Brazilian real 3.524).
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.